Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Incyte Corporation presented at the RBC Capital Markets Global Healthcare Conference 2026. The presentation featured Steven Stein, the Executive VP and Chief Medical Officer, discussing the company's pipeline and recent developments. Key topics included the Phase III plans for their drug 989 for essential thrombocythemia (ET).
- ▪Incyte Corporation participated in the RBC Capital Markets Global Healthcare Conference 2026.
- ▪Steven Stein, the Executive VP and Chief Medical Officer, led the presentation.
- ▪The discussion included updates on the company's drug 989 for essential thrombocythemia.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906553-incyte-corporation-incy-presents-at-rbc-capital-markets-global-healthcare-conference-2026"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
